Want to see IL:BOLT full AI Analyst Report?
Top Page
Biolight
(TASE:BOLT)
Select Model
Select Model
Rating:49Neutral
Price Target:
393.00
▼(-6.89% Downside)
Action:Reiterated
Date:06/16/26
Overall score is held back primarily by weak financial performance (zero/volatile revenue, persistent losses, and ongoing cash burn despite low leverage). Technicals are relatively supportive in the near-to-intermediate term, but valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Very low leverage
Persistent very low debt ratios materially reduce refinancing and interest-rate exposure, giving the company structural financial flexibility. Over 2–6 months this lowers default risk and preserves optionality for R&D funding or strategic partnerships without urgent debt servicing pressures.
Negative Factors
Revenue fell to zero in 2025
A drop to zero reported revenue is a fundamental weakness for a commercial trajectory: it signals absent or stalled product sales and undermines scalability. Over the medium term this makes reaching sustainable margins unlikely without clear revenue re‑acceleration or new commercial channels.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Persistent very low debt ratios materially reduce refinancing and interest-rate exposure, giving the company structural financial flexibility. Over 2–6 months this lowers default risk and preserves optionality for R&D funding or strategic partnerships without urgent debt servicing pressures.
Read all positive factors
Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪30.69M
Dividend YieldN/A
Average Volume (3M)11.86K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth-100.00%
EPS Growth-29.02%
CountryIL
Employees4
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolight Business Overview & Revenue Model
Company Description
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline incl...
How the Company Makes Money
null...
Biolight Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 219.00K | 118.00K | 63.00K | 3.00K |
| Gross Profit | -544.00K | 219.00K | 118.00K | 63.00K | 3.00K |
| EBITDA | -14.66M | -7.75M | -10.60M | -8.03M | -1.31M |
| Net Income | -11.73M | -7.14M | -26.02M | -7.85M | 382.00K |
Balance Sheet | |||||
| Total Assets | 42.41M | 34.12M | 33.45M | 57.01M | 64.17M |
| Cash, Cash Equivalents and Short-Term Investments | 23.65M | 13.47M | 8.64M | 17.63M | 33.71M |
| Total Debt | 772.00K | 599.00K | 91.00K | 527.00K | 443.00K |
| Total Liabilities | 2.24M | 3.38M | 3.15M | 3.32M | 2.75M |
| Stockholders Equity | 34.40M | 26.88M | 29.78M | 53.17M | 60.70M |
Cash Flow | |||||
| Free Cash Flow | -10.86M | -11.02M | -10.99M | -9.64M | -10.65M |
| Operating Cash Flow | -10.85M | -10.99M | -9.58M | -9.54M | -10.03M |
| Investing Cash Flow | -16.17M | 7.55M | -1.95M | -10.55M | 13.48M |
| Financing Cash Flow | 21.37M | 7.98M | 3.25M | -485.00K | 915.00K |
Biolight Technical Analysis
Negative
422.10
Price Trends
362.98
Negative
322.22
Positive
343.96
Negative
Market Momentum
-9.51
Positive
38.27
Neutral
20.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 422.1 is above the 20-day moving average (MA) of 380.22, above the 50-day MA of 362.98, and above the 200-day MA of 343.96, indicating a bearish trend. The MACD of -9.51 indicates Positive momentum. The RSI at 38.27 is Neutral, neither overbought nor oversold. The STOCH value of 20.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.
Biolight Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₪39.31M | -1.39 | ― | ― | -94.40% | 31.61% | |
49 Neutral | ₪30.69M | -1.71 | ― | ― | -100.00% | -29.02% | |
46 Neutral | ₪21.47M | -0.72 | ― | ― | ― | ― | |
43 Neutral | ₪32.42M | >-0.01 | ― | ― | ― | -125.74% |
* General Sector Average
IL:BOLT
Biolight
332.60
-177.90
-34.85%
IL:BONS
Bonus Biogroup
21.80
-3.40
-13.49%
IL:CBI
Clal Biotech
24.00
-7.60
-24.05%
IL:BLRX
Bioline Rx
1.50
-0.60
-28.57%
IL:CANF
Can Fite Bio
515.50
514.50
51450.00%
IL:PPBT
Purple Biotech
1.00
-2.70
-72.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.